2021 Pipeline Insights on the Desmoid Tumors Market – ResearchAndMarkets.com

2021 Pipeline Insights on the Desmoid Tumors Market – ResearchAndMarkets.com

2021 Pipeline Insights on the Desmoid Tumors Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Desmoid Tumors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


The symptoms of Desmoid Tumors include:

  • A mass or area of swelling
  • Pain
  • Loss of function in the affected area
  • Pain and obstruction of the bowels
  • Cramping and nausea, when desmoid tumors occur in the abdomen


A diagnosis of Desmoid Tumors is based upon a thorough physical examination and specialized tests. Test like imaging tests, such as CT and MRI are done. Biopsy is done to make a definitive diagnosis. Antibodies are often examined in desmoid tumors, including smooth muscle actin, desmin and KIT, to aid in distinguishing them from other tumors.


Some desmoid tumors are slow growing and don’t require immediate treatment. Others that grow quickly are treated with surgery, radiation therapy, chemotherapy including anticancer drugs, cryoablation or through combinatorial therapy. Anti-inflammatory drugs may cause the tumor to slowly shrink. Chemotherapy agents used to inhibit growth include Doxorubicin (Adriamycin, Rubex), Dacarabazine (DTIC-Dome) and Carboplatin (Paraplatin). Gleevec and Sorafenib are the two kinase inhibitors that are useful in treating desmoid tumors.

Desmoid Tumors Emerging Drugs Chapters

This segment of the Desmoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Desmoid Tumors Emerging Drugs

Nirogacestat: SpringWorks Therapeutics

Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor. It is currently in Phase 3 clinical development for patients with desmoid tumors. The U. S. FDA has granted nirogacestat Orphan Drug Designation for the treatment of desmoid tumors and Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Tegavivint: Iterion Therapeutics

Tegavivint is a potent and selective inhibitor of nuclear β-catenin that binds to TBL1 (Transducin βeta-like Protein One). This enables specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions and thus avoids toxicity issues common to other drugs in this pathway. Tegavivint is currently in Phase 2a clinical trial in progressive desmoid tumors after establishing safety and initial clinical efficacy in Phase 1 study.

Desmoid Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Desmoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Desmoid Tumors

There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i. e. phase III include, SpringWorks Therapeutics.


This report covers around 12+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Desmoid Tumors drugs?
  • How many Desmoid Tumors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Desmoid Tumors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Desmoid Tumors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Desmoid Tumors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • SpringWorks Therapeutics
  • Iterion Therapeutics
  • Cellestia Biotech
  • BioSpecifics Technologies Corp.
  • 180 Life Sciences
  • AFT Pharma
  • Timber Pharmaceuticals
  • MedPacto
  • Intas Pharmaceuticals
  • Jina pharmaceuticals

Key Products

  • Nirogacestat
  • Tegavivint
  • CB-103
  • Collagenase injection
  • Adalimumab
  • Sirolimus topical
  • Vactosertib
  • Endoxifen

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jp4784



Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900